Endo International plc announced that the Tennessee Court of Appeals reversed a trial court judge’s order denying a motion for recusal by Endo’s wholly owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc. in Clay County et al. v. Purdue Pharma, L.P., et al, pending in the Circuit Court for Cumberland County, Tennessee, and remanded the case for transfer to a different judge.
The White House said on Nov. 4 that understanding the origins of Covid-19 remains a key focus of the Biden administration and that they will continue pushing for answers.
Despite a high-profile visit to China by a team of international experts in January, the world is no closer to knowing the origins of Covid-19, according to one of the authors of an open letter calling for a new investigation into the pandemic.
New York state filed civil charges accusing Johnson & Johnson of insurance fraud for downplaying the risks of opioid painkillers, including to doctors and elderly patients.
Novartis said claims of price fixing against the drugmaker’s Sandoz generics unit amid a U.S. probe of 20 drugmakers are without merit, with the Swiss company vowing to fight allegations in a lawsuit.
A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States amid a wider probe into cancer risks associated with the drug.
Changsheng Bio-technology Co. Ltd., a Chinese vaccine maker accused of falsifying data, plunged deeper into crisis with police detaining its chairwoman and the country’s top graft watchdog launching investigations into the firm.
China’s drug control agency on Monday said the United States should do more to cut its demand for opioids to tackle the use of the synthetic drug fentanyl, but it vowed to step up cooperation after Chinese production of the substance was blamed for fueling the U.S. opioid crisis.
Britain’s Indivior was subpoenaed by the California Department of Insurance over its blockbuster opioid addiction treatment Suboxone Film, which is rapidly losing market share due to stiff competition from generic versions.
Jazz Pharmaceuticals Plc agreed to pay $57 million to resolve a U.S. probe into the company’s financial support of charities that offer assistance to Medicare patients seeking help to cover out-of-pocket drug costs.